AI-Driven Drug Discovery Platforms Market

AI-Driven Drug Discovery Platforms Market Share & Analysis – Industry Overview

Base Year: 2024 Historical Data: 2021-23
  • Report ID: TBI-14778
  • Published Date: Jun, 2025
  • Pages: 237
  • Category: Information Technology & Semiconductors
  • Format: PDF
Buy @ $4700.00 Request Sample PDF

Segment Analysis

Regional segmentation analysis

The regions analyzed for the market include North America, Europe, South America, Asia Pacific, the Middle East, and Africa. North America emerged as the most significant global AI-driven drug discovery platforms market, with a 41% market revenue share in 2024.

This market is largely dominated by North America because it has well-developed healthcare sector, advanced technology and substantial capital and effort that is invested into research and development. The area gains from several top pharmaceutical and biotech companies as well as from AI startups working on advanced drug discovery methods. The generous financial support from the public and private players significantly augments the market’s growth. There are strong and evolving safety rules in the region, headed by the FDA, to help AI technology gain clearance and approval. Because of this regulation, companies no longer worry so much and are more willing to use AI-based systems. Highly skilled experts in AI, machine learning and biomedical fields are available in North America which helps in developing AI tools for drug discovery a much easier and speedier process. Besides, AI’s impressive data-handling and prediction skills are useful for the North American market’s shift towards personalized treatments. Because of these advantages—strong innovation, financial support, friendly rules, good talent and healthcare focus—North America is at the forefront of the AI-driven drug discovery market worldwide.

North America Region AI-Driven Drug Discovery Platforms Market Share in 2024 - 41%

 

www.thebrainyinsights.com

Check the geographical analysis of this market by requesting a free sample

  • Elix, Inc., a company focused on AI drug discovery and dedicated to the mission of “Rethinking Drug Discovery”, has announced a collaboration with PRISM BioLab, Co. Ltd. for drug discovery, effective April 1, 2025.  By merging Elix's state-of-the-art AI drug discovery platform with PRISM BioLab's exclusive peptide mimetic technology for regulating protein-protein interactions, this collaboration will expedite research on these difficult molecular targets.  This collaboration will see the integration of Elix Discovery, Elix's AI drug discovery platform, with PRISM BioLab's proprietary small molecule peptide-mimetic PepMetics technology. With this collaboration, the realm of AI-driven exploration will encompass small molecules that were not considered before. This will facilitate the effective identification of promising compounds for targets that are traditionally challenging and expedite the development of breakthrough drug candidates.

Component Segment Analysis

The component segment is divided into software, hardware and services. The software segment dominated the market, with a market share of around 40% in 2024. The main reason behind software’s dominance in the market is its support in many stages in drug discovery. AI applications in the drug development area rely on software solutions to supply the main algorithms, tools for data processing and computational models for fast and precise selection of potential drugs. Software platforms give pharmacies scalable, repeatable and customizable tools they can build right into their research routines making them highly sought after components in the market. A major reason for software’s success is that it can process and study large and complicated biological data far more productively than traditional methods which saves both money and time. All in all, the AI-driven drug discovery market relies heavily on software because it scales well, is efficient, can handle large data and drives both innovation and productivity in modern drug development.

  • Rubedo Life Sciences, Inc. (Rubedo), a biotech company in the clinical stage that is driven by AI and aims to find and swiftly develop selective cellular rejuvenation therapies aimed at aging cells, has announced that opensource codes incorporated into its proprietary drug discovery platform, ALEMBIC, facilitated the identification of senescent neurons in a new study showing that these neurons are responsible for chronic pain resulting from injury and aging.

Application Segment Analysis

The application segment is divided into target identification, drug design & optimization, preclinical testing and clinical trials support. The target identification segment dominated the market, with a market share of around 35% in 2024. Recognizing and confirming which proteins, genes or pathways play a role in disease is necessary for creating good drugs. With AI, it becomes possible to quickly and accurately scan much more information about biological, chemical and clinical data than standard methods can handle. AI is applied in platforms for target identification to find important information hidden in big datasets, including genomics, proteomics and transcriptomics. Researchers can detect targets and biomarkers connected to particular diseases which helps design medicines with improved results and lower risks. Companies in the pharmaceutical sector emphasize this step, since it supports every following drug development activity and is why they make up most of the market. The main reason for this is that target identification plays a crucial part in drug development, is greatly influenced by AI and is key to the development of precision medicine initiatives.

Technology Segment Analysis

The technology segment is divided into machine learning, deep learning and natural language processing (NLP)). The machine learning segment dominated the market, with a market share of around 39% in 2024. The reason ML is most popular in the drug discovery platforms market is its flexibility, strong performance and versatile use throughout the drug development process. Much like other AI technologies, ML algorithms are great at handling huge amounts of data, making patterns that are hard to notice with normal statistics easier to find. Another advantage is that machine learning models need less processing power enabling them to be used in many places regardless of limited resources. As a result, small and mid-sized companies are picking up AI at a faster pace to save money. In addition, ML is able to process genomic, proteomic, chemical and health data from patients, giving a complete picture of both drug action and patient responses. By collecting detailed knowledge, it is possible to make better choices at every step in drug development. Overall, machine learning’s effectiveness is based on being flexible, efficient, scalable and reliable in generating usable insights which is why it is chosen to drive drug discovery and speed up pharmaceutical innovation.

  • Charles River Laboratories International, Inc. and Valo Health, Inc. announced the discovery of a product candidate that can be advanced for treating various types of lupus and other autoimmune conditions where there is a considerable unmet need. This discovery marks the first application of Logica, a drug development solution powered by artificial intelligence (AI) that converts biological insights into optimized preclinical assets.

Therapeutic area Segment Analysis

The therapeutic area segment is divided into oncology, neurology, infectious diseases, cardiovascular diseases and others. The oncology segment dominated the market, with a share of around 37% in 2024. Among all therapeutic areas, oncology leads in the AI-driven drug discovery platforms market because of the various challenges, how common cancer is and how urgent the care requirements are. Cancer involves many kinds of genetic changes, different tumour surroundings and various patient responses making it extremely challenging to find effective drugs for cancer. AI used in oncology can look through many different types of data, from genetic records to clinical information, to discover new drug targets, estimate treatment results and customize care. The increase in oncology is largely due to a greater effort and more money devoted to developing cancer drugs. Many companies and research institutions are prioritizing oncology because of a large group of cancer patients, high cancer-related deaths and the big benefits of successful cancer treatments on the market. AI helps quickly detect important connections in how tumours act and in patients’ information which allows experts to develop better targeted therapies with fewer side effects. In addition, precision medicine which tests DNA and RNA to design treatments for specific patients, is developing rapidly in oncology. Through use of AI, this process becomes much easier. In addition, government entities now favour new oncology therapies which also augment’s the segment’s growth. The field of oncology commands the AI-driven drug discovery market mostly because cancer is complex to treat, there are big gaps in care, there is rapid rise in cancer patients and plenty of funding is provided for cancer research.

End-User Segment Analysis

The end-user segment is divided into pharmaceutical & biotechnology companies, contract research organizations (CROs) and academic & research institutes. The pharmaceutical & biotechnology companies segment dominated the market, with a share of around 44% in 2024. Most of the AI-driven drug discovery platforms are used by pharmaceutical and biotechnology companies, who depend on them to stay ahead in the market with new drugs, medication, therapies and treatments. They can make use of AI technologies in drug discovery because they have enough resources, rich private data and competent staff. Since bringing a new drug to the market is both difficult and expensive, AI-based tools are being used by these companies to make the process more efficient, faster and successful. In addition, the need to innovate due to rising competition and the interest in providing specific treatments motivates these companies. Overall, the main companies in this market are pharmaceutical and biotechnology firms that lead with their major role in drug development, strong investments, focus on new ideas and direct advantages from applying AI to discovering drugs.

Request Table of Content

+1

This study forecasts revenue at global, regional, and country levels from 2021 to 2034. The Brainy Insights has segmented the global AI-driven drug discovery platforms market based on below mentioned segments:

Global AI-Driven Drug Discovery Platforms Market by Component:

  • Software
  • Hardware
  • Services

Global AI-Driven Drug Discovery Platforms Market by Application:

  • Target Identification
  • Drug Design & Optimization
  • Preclinical Testing
  • Clinical Trials Support

Global AI-Driven Drug Discovery Platforms Market by Technology:

  • Machine Learning
  • Deep Learning
  • Natural Language Processing (NLP)

Global AI-Driven Drug Discovery Platforms Market by Therapeutic Area:

  • Oncology
  • Neurology
  • Infectious Diseases
  • Cardiovascular Diseases
  • Others

Global AI-Driven Drug Discovery Platforms Market by End-User:

  • Pharmaceutical & Biotechnology Companies
  • Contract Research Organizations (CROs)
  • Academic & Research Institutes

Global AI-Driven Drug Discovery Platforms Market by Region:

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
  • Asia-Pacific
    • Japan
    • China
    • India
  • South America
    • Brazil
  • Middle East and Africa  
    • UAE
    • South Africa

Methodology

Research has its special purpose to undertake marketing efficiently. In this competitive scenario, businesses need information across all industry verticals; the information about customer wants, market demand, competition, industry trends, distribution channels etc. This information needs to be updated regularly because businesses operate in a dynamic environment. Our organization, The Brainy Insights incorporates scientific and systematic research procedures in order to get proper market insights and industry analysis for overall business success. The analysis consists of studying the market from a miniscule level wherein we implement statistical tools which helps us in examining the data with accuracy and precision. 

Our research reports feature both; quantitative and qualitative aspects for any market. Qualitative information for any market research process are fundamental because they reveal the customer needs and wants, usage and consumption for any product/service related to a specific industry. This in turn aids the marketers/investors in knowing certain perceptions of the customers. Qualitative research can enlighten about the different product concepts and designs along with unique service offering that in turn, helps define marketing problems and generate opportunities. On the other hand, quantitative research engages with the data collection process through interviews, e-mail interactions, surveys and pilot studies. Quantitative aspects for the market research are useful to validate the hypotheses generated during qualitative research method, explore empirical patterns in the data with the help of statistical tools, and finally make the market estimations.

The Brainy Insights offers comprehensive research and analysis, based on a wide assortment of factual insights gained through interviews with CXOs and global experts and secondary data from reliable sources. Our analysts and industry specialist assume vital roles in building up statistical tools and analysis models, which are used to analyse the data and arrive at accurate insights with exceedingly informative research discoveries. The data provided by our organization have proven precious to a diverse range of companies, facilitating them to address issues such as determining which products/services are the most appealing, whether or not customers use the product in the manner anticipated, the purchasing intentions of the market and many others.

Our research methodology encompasses an idyllic combination of primary and secondary initiatives. Key phases involved in this process are listed below:

MARKET RESEARCH PROCESS

Data Procurement:

The phase involves the gathering and collecting of market data and its related information with the help of different sources & research procedures.

The data procurement stage involves in data gathering and collecting through various data sources.

This stage involves in extensive research. These data sources includes:

Purchased Database: Purchased databases play a crucial role in estimating the market sizes irrespective of the domain. Our purchased database includes:

  • The organizational databases such as D&B Hoovers, and Bloomberg that helps us to identify the competitive scenario of the key market players/organizations along with the financial information.
  • Industry/Market databases such as Statista, and Factiva provides market/industry insights and deduce certain formulations. 
  • We also have contractual agreements with various reputed data providers and third party vendors who provide information which are not limited to:
    • Import & Export Data
    • Business Trade Information
    • Usage rates of a particular product/service on certain demographics mainly focusing on the unmet prerequisites

Primary Research: The Brainy Insights interacts with leading companies and experts of the concerned domain to develop the analyst team’s market understanding and expertise. It improves and substantiates every single data presented in the market reports. Primary research mainly involves in telephonic interviews, E-mail interactions and face-to-face interviews with the raw material providers, manufacturers/producers, distributors, & independent consultants. The interviews that we conduct provides valuable data on market size and industry growth trends prevailing in the market. Our organization also conducts surveys with the various industry experts in order to gain overall insights of the industry/market. For instance, in healthcare industry we conduct surveys with the pharmacists, doctors, surgeons and nurses in order to gain insights and key information of a medical product/device/equipment which the customers are going to usage. Surveys are conducted in the form of questionnaire designed by our own analyst team. Surveys plays an important role in primary research because surveys helps us to identify the key target audiences of the market. Additionally, surveys helps to identify the key target audience engaged with the market. Our survey team conducts the survey by targeting the key audience, thus gaining insights from them. Based on the perspectives of the customers, this information is utilized to formulate market strategies. Moreover, market surveys helps us to understand the current competitive situation of the industry. To be precise, our survey process typically involve with the 360 analysis of the market. This analytical process begins by identifying the prospective customers for a product or service related to the market/industry to obtain data on how a product/service could fit into customers’ lives.

Secondary Research: The secondary data sources includes information published by the on-profit organizations such as World bank, WHO, company fillings, investor presentations, annual reports, national government documents, statistical databases, blogs, articles, white papers and others. From the annual report, we analyse a company’s revenue to understand the key segment and market share of that organization in a particular region. We analyse the company websites and adopt the product mapping technique which is important for deriving the segment revenue. In the product mapping method, we select and categorize the products offered by the companies catering to domain specific market, deduce the product revenue for each of the companies so as to get overall estimation of the market size. We also source data and analyses trends based on information received from supply side and demand side intermediaries in the value chain. The supply side denotes the data gathered from supplier, distributor, wholesaler and the demand side illustrates the data gathered from the end customers for respective market domain.

The supply side for a domain specific market is analysed by:

  • Estimating and projecting penetration rates through analysing product attributes, availability of internal and external substitutes, followed by pricing analysis of the product.
  • Experiential assessment of year-on-year sales of the product by conducting interviews.

The demand side for the market is estimated through:

  • Evaluating the penetration level and usage rates of the product.
  • Referring to the historical data to determine the growth rate and evaluate the industry trends

In-house Library: Apart from these third-party sources, we have our in-house library of qualitative and quantitative information. Our in-house database includes market data for various industry and domains. These data are updated on regular basis as per the changing market scenario. Our library includes, historic databases, internal audit reports and archives.

Sometimes there are instances where there is no metadata or raw data available for any domain specific market. For those cases, we use our expertise to forecast and estimate the market size in order to generate comprehensive data sets. Our analyst team adopt a robust research technique in order to produce the estimates:

  • Applying demographic along with psychographic segmentation for market evaluation
  • Determining the Micro and Macro-economic indicators for each region 
  • Examining the industry indicators prevailing in the market. 

Data Synthesis: This stage involves the analysis & mapping of all the information obtained from the previous step. It also involves in scrutinizing the data for any discrepancy observed while data gathering related to the market. The data is collected with consideration to the heterogeneity of sources. Robust scientific techniques are in place for synthesizing disparate data sets and provide the essential contextual information that can orient market strategies. The Brainy Insights has extensive experience in data synthesis where the data passes through various stages:

  • Data Screening: Data screening is the process of scrutinising data/information collected from primary research for errors and amending those collected data before data integration method. The screening involves in examining raw data, identifying errors and dealing with missing data. The purpose of the data screening is to ensure data is correctly entered or not. The Brainy Insights employs objective and systematic data screening grades involving repeated cycles of quality checks, screening and suspect analysis.
  • Data Integration: Integrating multiple data streams is necessary to produce research studies that provide in-depth picture to the clients. These data streams come from multiple research studies and our in house database. After screening of the data, our analysts conduct creative integration of data sets, optimizing connections between integrated surveys and syndicated data sources. There are mainly 2 research approaches that we follow in order to integrate our data; top down approach and bottom up approach.

Market Deduction & Formulation: The final stage comprises of assigning data points at appropriate market spaces so as to deduce feasible conclusions. Analyst perspective & subject matter expert based holistic form of market sizing coupled with industry analysis also plays a crucial role in this stage.

This stage involves in finalization of the market size and numbers that we have collected from data integration step. With data interpolation, it is made sure that there is no gap in the market data. Successful trend analysis is done by our analysts using extrapolation techniques, which provide the best possible forecasts for the market.

Data Validation & Market Feedback: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helps us finalize data-points to be used for final calculations.

The Brainy Insights interacts with leading companies and experts of the concerned domain to develop the analyst team’s market understanding and expertise. It improves and substantiates every single data presented in the market reports. The data validation interview and discussion panels are typically composed of the most experienced industry members. The participants include, however, are not limited to:

  • CXOs and VPs of leading companies’ specific to sector
  • Purchasing managers, technical personnel, end-users
  • Key opinion leaders such as investment bankers, and industry consultants

Moreover, we always validate our data and findings through primary respondents from all the major regions we are working on.

Some Facts About The Brainy Insights

50%

Free Customization

300+

Fortune 500 Clients

1

Free Yearly Update On Purchase Of Multi/Corporate License

900+

Companies Served Till Date